Navigation Links
Keppra XR(TM) Extended-Release Tablets Filed with the FDA
Date:1/16/2008

older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Keppra(R) injection is indicated as adjunctive therapy in the treatment of myoclonic seizures in juvenile myoclonic epilepsy and partial onset seizures in adults with epilepsy. Keppra(R) injection is an alternative for patients when oral administration is temporarily not feasible.

Keppra(R) tablets and oral solution are associated with the occurrence of central nervous system adverse events including somnolence and fatigue, behavioral abnormalities, as well as hematological abnormalities. In adults experiencing partial onset seizures, Keppra(R) is also associated with coordination difficulties. In adults experiencing partial onset seizures, the most common adverse events associated with Keppra(R) in combination with other AEDs were somnolence, asthenia, infection and dizziness. In pediatric patients 4-16 years of age experiencing partial onset seizures, the most common adverse events associated with Keppra(R) in combination with other AEDs were somnolence, accidental injury, hostility, nervousness and asthenia. In patients 12 years of age and older with juvenile myoclonic epilepsy, the most common adverse events associated with Keppra(R) in combination with other AEDs were somnolence, neck pain, and pharyngitis. In patients 6 years of age and older with idiopathic generalized epilepsy, the most common adverse event associated with Keppra(R) in combination with other AEDs was nasopharyngitis.

The adverse events that result from Keppra(R) injection use for myoclonic seizures in juvenile myoclonic epilepsy and partial onset seizures in adults include all of those associated with Keppra(R) tablets and oral solution.

U.S. prescribing information is available at http://www.keppra.com or by calling 1-866-822-0068.

Furthe
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
2. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
3. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
4. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
5. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... May 23, 2013 Amgen (NASDAQ: AMGN ... Annual  Healthcare Conference on Thursday, May 30, 2013, at the ... at 9:20 a.m. Eastern Daylight Time. Arvind Sood ... present at the conference. Live audio of the presentation can ... www.amgen.com , under Investors. A replay of the webcast will ...
(Date:5/23/2013)... Nephros, Inc. (OTC Bulletin Board: ... develops and sells high performance liquid purification ultrafilters, announced ... addition, the concurrent temporary reduction in exercise price for ... 2013. Nephros estimates that it will receive ... A portion of the proceeds will be used for ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ... CSKI ), a leading fully integrated pharmaceutical company ... ("PRC"), today announced that it held its 2011 Annual ... 2011, in Harbin, PRC. At the Annual ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") ... in-vitro diagnostic ("IVD") company, today announced that China,s State ... Company,s real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma viral oncogene ... companion diagnostic test for the use of a targeted ...
Cached Medicine Technology:China Sky One Medical, Inc. Elects Board Directors at its Annual Shareholders Meeting 2China Medical Technologies Receives SFDA Approval for its PCR-based KRAS Assay for Colorectal Cancer Targeted Drug 2
(Date:5/23/2013)... May 23, 2013 Susquehanna Health ... offering a comprehensive babysitting training course for adolescents age ... developed by Indianapolis pediatrician Dr. Patricia Keener after a ... of an adult sitter who didn’t know how to ... development program with a medical basis that aims to ...
(Date:5/23/2013)... - Even while being dragged to its destruction ... fires away, sending signals that thwart the development ... reported in an early online publication at ... often encountered by tumors, the epidermal growth factor ... an international team led by scientists at The ...
(Date:5/23/2013)... Clinic researchers have used next generation genomic analysis to ... tumors have similar genetic origins, which may help in ... the journal Cancer Research . , "This is ... generation sequencing in adjacent Gleason patterns in the same ... pathology," says ,John Cheville, M.D., Mayo Clinic pathologist and ...
(Date:5/23/2013)... Rottenstein Law Group LLP, a New York-based nationwide mass ... Center at http://www.rotlaw.com/tylenol , dedicated to issues that ... filing lawsuits. , The painkiller Tylenol (acetaminophen) has ... to a 2009 report from the U.S. Food and ... warned consumers against using more than the recommended dose ...
(Date:5/23/2013)... Dr. Katherine Ahn is proud to ... County, OCCares , will hold its first community event ... details are as follows: , Sunday May 26th, 2013 from ... Garden Grove, CA 92843 , The benefit celebration will feature ... Charmaine & Jonathan Thulin. There will also be piano, ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3
... failure by official bodies to halt the distribution of ... been incidents caused by E. coli contamination in ... food. , Around 200 persons were affected ... was the collapse of both kidneys of a three-year-old ...
... huge doping scam burst into the open in Paris, ... suspended for three months by the// Californian state authorities. ... the Bay Area Laboratory Co-Operative that allegedly provided steroids ... placed on five years' probation and ordered to undergo ...
... increased rates of serious infections caused by strains ... the current childhood pneumococcal vaccine,// according to a ... conjugate vaccine (PCV7), Alaska Native children and adults ... compared with non–Native Alaskans. Introduction of PCV7 into ...
... Stroke patients in rural hospitals can get safe, effective ... a doctor from a larger hospital is on the ... implications for overcoming barriers to optimal stroke care in ... of this treatment over the telephone appears to be ...
... experience hot flashes: unpredictable, sometimes disruptive, periods of intense ... generations of physicians have prescribed hormones to reduce these ... causes of hot flashes. ,Three new studies explore ... contributing to – or lessening – the intensity and ...
... medical representatives needs no introduction. The motivation for such ... and boardrooms, where jet-setting corporate executives are given their ... sheer bottom-line figures, the dynamic medical rep gets to ... medical representatives first create a ready reckoner of the ...
Cached Medicine News:Health News:U.S Officials Worried Over Failure In Preventing Food Contamination 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 3Health News:Increase in Pneumococcal Infections That are Not Covered by Vaccine 2Health News:Hot Flashes: Studies Explore the Various Possibilities Involved 2Health News:Hot Flashes: Studies Explore the Various Possibilities Involved 3Health News:Art of Establishing a Bond to Sell a Brand – Medical Reps Show the Wa 2
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... Sugar-Chex Linearity is a whole blood ... reportable range of the most popular ... recommendations of using a control matrix ... Linearity is packaged in ready-to-use dropper ...
Medicine Products: